

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1061)

GRANT OF SHARE OPTIONS

This announcement is made pursuant to Rule 17.06A of the Rules (“**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”).

The board (“**Board**”) of directors (“**Directors**”) of Essex Bio-Technology Limited (“**Company**”, together with its subsidiaries, the “**Group**”) announces that on 27 June 2018, the Company has granted to an eligible person (“**Grantee**”), subject to acceptance by such Grantee, share options (“**Share Options**”) to subscribe for up to 1,000,000 ordinary shares of HK\$0.1 each in the share capital of the Company (each, a “**Share**”) under the share option scheme adopted by the Company on 3 May 2013. Payment of HK\$1.00 will be made by the Grantee upon acceptance of the Share Options.

Details of the Options are set out below pursuant to Rule 17.06A of the Listing Rules:

Date of grant	:	27 June 2018 (“ Date of Grant ”)
Exercise price of the Share Options granted	:	HK\$10.00 per Share (not less than the highest of (i) the closing price of HK\$6.20 per Share as stated in the Stock Exchange’s daily quotations sheet on the Date of Grant; (ii) the average closing price of HK\$6.55 per Share as stated in the Stock Exchange’s daily quotations sheets for the five business days immediately preceding the Date of Grant; and (iii) the nominal value of HK\$0.10 per Share)
Number of Share Options granted	:	1,000,000 Share Options, each Share Option entitling the holder thereof to subscribe for one Share at the exercise price mentioned above

- Closing price of the Share : HK\$6.20 per Share
on the Date of Grant
- Validity period of the Share : From the Date of Grant to 26 June 2023 (both dates inclusive)
Options granted
- Exercise periods of the : The Grantee is entitled to exercise the Share Options in accordance
Share Options with the following vesting periods and in the following manner:
- (a) up to 30% of the total number of Share Options granted to the Grantee is exercisable during the period from 27 June 2020 to 26 June 2023 (both dates inclusive);
 - (b) up to 30% of the total number of Share Options granted to the Grantee is exercisable during the period from 27 June 2021 to 26 June 2023 (both dates inclusive);
 - (c) up to 40% of the total number of Share Options granted to the Grantee is exercisable during the period from 27 June 2022 to 26 June 2023 (both dates inclusive);

All outstanding or unexercised Share Options granted to the Grantee shall lapse after 26 June 2023.

The Grantee is neither a Director, chief executive or substantial shareholder of the Company, nor any of their respective associates.

On behalf of the Board
Essex Bio-Technology Limited
Ngiam Mia Je Patrick
Chairman

Hong Kong, 27 June 2018

Executive directors of the Company as at the date of this announcement are Mr. Ngiam Mia Je Patrick, Mr. Fang Haizhou and Mr. Zhong Sheng. Independent non-executive directors of the Company as at the date of this announcement are Mr. Fung Chi Ying, Mr. Mauffrey Benoit Jean Marie and Ms. Yeow Mee Mooi.